Bjorkstrom, N. K., Strunz, B. & Ljunggren, H. G. Natural killer cells in antiviral immunity. Nat. Rev. Immunol. 22, 112–123 (2022).

Article  PubMed  Google Scholar 

Mace, E. M. et al. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56bright subset. Blood 121, 2669–2677 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biron, C. A., Byron, K. S. & Sullivan, J. L. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320, 1731–1735 (1989).

Article  CAS  PubMed  Google Scholar 

Mace, E. M. et al. Biallelic mutations in IRF8 impair human NK cell maturation and function. J. Clin. Invest. 127, 306–320 (2017).

Article  PubMed  Google Scholar 

Cottineau, J. et al. Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. J. Clin. Invest. 127, 1991–2006 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Gineau, L. et al. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J. Clin. Invest. 122, 821–832 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grier, J. T. et al. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J. Clin. Invest. 122, 3769–3780 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cooper, M. A. et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood 97, 3146–3151 (2001).

Article  CAS  PubMed  Google Scholar 

Fehniger, T. A. et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101, 3052–3057 (2003).

Article  CAS  PubMed  Google Scholar 

Michel, T. et al. Human CD56bright NK cells: an update. J. Immunol. 196, 2923–2931 (2016).

Article  CAS  PubMed  Google Scholar 

Lopez-Verges, S. et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116, 3865–3874 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kee, B. L., Morman, R. E. & Sun, M. Transcriptional regulation of natural killer cell development and maturation. Adv. Immunol. 146, 1–28 (2020).

CAS  PubMed  Google Scholar 

Ramirez, K. et al. Gene deregulation and chronic activation in natural killer cells deficient in the transcription factor ETS1. Immunity 36, 921–932 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daussy, C. et al. T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. J. Exp. Med. 211, 563–577 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jeevan-Raj, B. et al. The transcription factor Tcf1 contributes to normal NK cell development and function by limiting the expression of granzymes. Cell Rep. 20, 613–626 (2017).

Article  CAS  PubMed  Google Scholar 

Boos, M. D., Yokota, Y., Eberl, G. & Kee, B. L. Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity. J. Exp. Med. 204, 1119–1130 (2007).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gascoyne, D. M. et al. The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat. Immunol. 10, 1118–1124 (2009).

Article  CAS  PubMed  Google Scholar 

Kamizono, S. et al. Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. J. Exp. Med. 206, 2977–2986 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holmes, T. D. et al. The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiation. Sci. Immunol. 6, eabc9801 (2021).

Wiedemann, G. M. et al. Deconvoluting global cytokine signaling networks in natural killer cells. Nat. Immunol. 22, 627–638 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rautela, J., Surgenor, E. & Huntington, N. D. Drug target validation in primary human natural killer cells using CRISPR RNP. J. Leukoc. Biol. 108, 1397–1408 (2020).

Article  CAS  PubMed  Google Scholar 

Riggan, L. et al. CRISPR–Cas9 ribonucleoprotein-mediated genomic editing in mature primary innate immune cells. Cell Rep. 31, 107651 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Collins, P. L. et al. Gene regulatory programs conferring phenotypic identities to human NK cells. Cell 176, 348–360 (2019).

Article  CAS  PubMed  Google Scholar 

Khameneh, H. J. et al. Myc controls NK cell development, IL-15-driven expansion, and translational machinery. Life Sci. Alliance 6, e202302069 (2023).

Li, Z. Y. et al. The transcriptional repressor ID2 supports natural killer cell maturation by controlling TCF1 amplitude. J. Exp. Med. 218, e20202032 (2021).

van Helden, M. J. et al. Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection. J. Exp. Med. 212, 2015–2025 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Okada, S. et al. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science 349, 606–613 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cooley Coleman, J. A. et al. Comprehensive investigation of the phenotype of MEF2C-related disorders in human patients: a systematic review. Am. J. Med. Genet. A 185, 3884–3894 (2021).

Article  PubMed  Google Scholar 

Harrington, A. J. et al. MEF2C hypofunction in neuronal and neuroimmune populations produces MEF2C haploinsufficiency syndrome-like behaviors in mice. Biol. Psychiatry 88, 488–499 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin, Q., Schwarz, J., Bucana, C. & Olson, E. N. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 276, 1404–1407 (1997).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mitrovic, M. et al. The NK cell response to mouse cytomegalovirus infection affects the level and kinetics of the early CD8+ T-cell response. J. Virol. 86, 2165–2175 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weizman, O. E. et al. ILC1 confer early host protection at initial sites of viral infection. Cell 171, 795–808 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mah, A. Y. et al. Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control. JCI Insight 2, e95128 (2017).

Marcais, A. et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat. Immunol. 15, 749–757 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonacina, F. et al. The low-density lipoprotein receptor–mTORC1 axis coordinates CD8+ T cell activation. J. Cell Biol. 221, e202202011 (2022).

Shimano, H. & Sato, R. SREBP-regulated lipid metabolism: convergent physiology—divergent pathophysiology. Nat. Rev. Endocrinol. 13, 710–730 (2017).

Article  CAS  PubMed  Google Scholar 

Martin-Rufino, J. D. et al. Massively parallel base editing to map variant effects in human hematopoiesis. Cell 186, 2456–2474 (2023).

Article  CAS  PubMed  Google Scholar 

McAuley, G. E. et al. Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing. Cell 186, 1398–1416 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng, J. et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science 381, eadg7492 (2023).

Article  CAS  PubMed  Google Scholar 

Keating, S. E. et al. Metabolic reprogramming supports IFN-γ production by CD56bright NK cells. J. Immunol. 196, 2552–2560 (2016).

Article  CAS  PubMed  Google Scholar